Dr Julia Kenkre and Dr Holly Morgan explore the role of elevated lipoprotein(a) [Lp(a)] levels in cardiovascular risk, its measurement challenges, clinical implications, and the approach to management.
Dr Jemima Scott and Professor Chris Gale discuss the bidirectional relationship between heart and kidney disease, and how treatment strategies can be developed that address both cardiovascular and renal risk in these vulnerable patients.
Gayle Campbell and Professor Pardeep Jhund discuss secondary prevention for heart failure patients, including key topics such as preventing reinfarction, foundational anti-failure agents, managing worsening heart failure, and improving patient adherence using tools like MedTap.
Dr Paul Foley and Prof Terry McCormack share the key changes in the new ESC guidance on atrial fibrillation, hypertension and arterial disease.
AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.
Dr Sarah Birkhoelzer and Dr Aaron Henry discuss hot topics and late-breaking abstracts from across the congress.
AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.
In this masterclass, Dr Dermot Neely and Dr Jai Cegla discuss the why, when and how of measuring lipoprotein(a) [Lp(a)], the current management of people with elevated Lp(a) and the future prospects for treatment.
In this masterclass, Alison Pottle and Jai Cegla provide discuss screening for familial hypercholesterolaemia (FH), treatment advances in dyslipidaemia, the role of lipid apheresis in specific populations and the importance of patient education.
Watch Terry McCormack and Rani Khatib discuss the updates to lipid management guidelines to reduce the risk of cardiovascular disease and implications for clinical practice. They will provide an overview of which patients should be treated, outline the current lipid-lowering targets and introduce the range of suitable treatments.
Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.